{
  "title": "Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trialThe role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversiesTreatment guidelines in psoriatic arthritisTargeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomesExperiences and treatment preferences in patients with psoriatic arthritis: a cross-sectional study in the ArthritisPower registryImpact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and EuropeGroup for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritisEULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 updateMinimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumabMeasurement properties of the minimal disease activity criteria for psoriatic arthritisPrevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysisPhenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapyRole of Th17 cells in human autoimmune arthritisIL-17 receptor and its functional significance in psoriatic arthritisTargeting IL-17 in psoriatic arthritisDual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammationInterleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritisLong-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 studyBimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitisPathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathiesHeterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complexBimekizumab versus secukinumab in plaque psoriasisBimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patientsProgress in intra-articular therapyPermeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammationThe therapeutic potential of NanobodiesImproved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody TechnologyNanobodies and nanobody-based human heavy chain antibodies as antitumor therapeuticsNaturally occurring antibodies devoid of light chainsInfluence of molecular size on tissue distribution of antibody fragmentsA novel anti-TNF-\u03b1 drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritisIL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b studyA randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasisComparative genomic profiling of synovium versus skin lesions in psoriatic arthritisEfficacy and safety of ixekizumab with or without methotrexate in biologic-na\u00efve patients with psoriatic arthritis: 52-week results from SPIRIT-H2H studyPatient-reported outcomes in psoriatic arthritisA multicenter nominal group study to rank outcomes important to patients, and their representation in existing composite outcome measures for psoriatic arthritisAchieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients\u2019 health-related quality of life and productivitySecukinumab inhibition of interleukin-17A in patients with psoriatic arthritisIxekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialTrial of upadacitinib and adalimumab for psoriatic arthritisDifferential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic diseaseComparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysisBimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17FFormatted anti-tumor necrosis factor \u03b1 VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritisPsychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trialsSecukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialAdverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping reviewSuppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing T cells through modification of the intestinal microbiotaTH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitisDivergent functions of IL-17-family cytokines in DSS colitis: insights from a naturally-occurring human mutation in IL-17FRisk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sourcesA review of the safety of interleukin-17A inhibitor secukinumabLong-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance dataLong-term safety of ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsSafety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trialsSex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysisResponses to ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trialsAxial involvement in psoriatic arthritis: is it unique?American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritisA 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisA patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the psoriatic arthritis impact of disease (PsAID) questionnaire, a 13-country EULAR initiative",
  "pmcid": "12705426",
  "features": {
    "sample_size": {
      "present": true,
      "count": 10,
      "unique_matches": [
        "n\u2009=\u200939",
        "sample size",
        "n\u2009=\u200938",
        "n\u2009=\u20091"
      ],
      "examples": [
        {
          "match": "Sample size",
          "context": "ilable in Supplementary Note. Sample size was calculated based on the a"
        },
        {
          "match": "sample size",
          "context": "Based on these assumptions, a sample size of 40 patients in each of the"
        },
        {
          "match": "n\u2009=\u200939",
          "context": "ctive protein.aCalculated for n\u2009=\u200939 (excluding one patient with m"
        }
      ]
    },
    "randomization": {
      "present": true,
      "count": 8,
      "unique_matches": [
        "allocation",
        "randomise"
      ],
      "examples": [
        {
          "match": "randomise",
          "context": "preclinical experiments and a randomised placebo-controlled clinical"
        },
        {
          "match": "randomise",
          "context": "crosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-contr"
        },
        {
          "match": "randomise",
          "context": "aive to biologic treatment: a randomised, double-blind, placebo-contr"
        }
      ]
    },
    "blinding": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "blinded"
      ],
      "examples": [
        {
          "match": "blinded",
          "context": "d PBO; however, the study was blinded at the carton level. Patients"
        },
        {
          "match": "blinded",
          "context": "ons. All study personnel were blinded until week 12. The study incl"
        },
        {
          "match": "blinded",
          "context": "O when relevant to maintain a blinded Q2W dosing schedule. In the A"
        }
      ]
    },
    "allocation_concealment": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "interaction_subgroup": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "stratification",
        "heterogeneity"
      ],
      "examples": [
        {
          "match": "stratification",
          "context": "effects for treatment and the stratification factors (sex and prior biolog"
        },
        {
          "match": "stratification",
          "context": "xed effects for treatment and stratification factors (sex and prior biolog"
        },
        {
          "match": "heterogeneity",
          "context": "w with metaanalysisPhenotypic heterogeneity in psoriatic arthritis: towar"
        }
      ]
    },
    "variable_definitions": {
      "present": true,
      "count": 7,
      "unique_matches": [
        "outcome measure",
        "primary endpoint"
      ],
      "examples": [
        {
          "match": "outcome measure",
          "context": "ntation in existing composite outcome measures for psoriatic arthritisAchie"
        },
        {
          "match": "outcome measure",
          "context": "-derived and patient-reported outcome measure for assessing psoriatic arthr"
        },
        {
          "match": "primary endpoint",
          "context": "ve colitis) and diarrhea. The primary endpoint of the study was the proporti"
        }
      ]
    },
    "analysis_principles": {
      "present": true,
      "count": 5,
      "unique_matches": [
        "intention-to-treat",
        "itt"
      ],
      "examples": [
        {
          "match": "intention-to-treat",
          "context": "CI, confidence interval; ITT, intention-to-treat; NI, no induction; OR, odds r"
        },
        {
          "match": "ITT",
          "context": "sing all randomized patients (ITT population). The safety analy"
        },
        {
          "match": "ITT",
          "context": "based on all patients in the ITT population. For PASI, percent"
        }
      ]
    },
    "itt_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "software": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "error_measures": {
      "present": true,
      "count": 5,
      "unique_matches": [
        "standard deviation",
        "standard error"
      ],
      "examples": [
        {
          "match": "standard deviation",
          "context": "ment of Arthritis Pain; s.d., standard deviation; s.e., standard error; SLK, s"
        },
        {
          "match": "standard deviation",
          "context": "putation; PBO, placebo; s.d., standard deviation; s.e., standard error; SLK, s"
        },
        {
          "match": "standard error",
          "context": "imating treatment effects and standard errors. For the part B analysis, no"
        }
      ]
    },
    "multiplicity_correction": {
      "present": true,
      "count": 9,
      "unique_matches": [
        "control the family-wise error",
        "multiple testing",
        "bonferroni",
        "nominal",
        "no adjustment",
        "holm"
      ],
      "examples": [
        {
          "match": "Bonferroni",
          "context": "se arms included in ARGO, the Bonferroni\u2013Holm procedure was applied to"
        },
        {
          "match": "multiple testing",
          "context": "gression model. To adjust for multiple testing and control the family-wise e"
        },
        {
          "match": "Holm",
          "context": "luded in ARGO, the Bonferroni\u2013Holm procedure was applied to cont"
        }
      ]
    },
    "normality_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "p_values": {
      "present": true,
      "count": 22,
      "unique_matches": [
        "significance level",
        "p-value",
        "secondary endpoint"
      ],
      "examples": [
        {
          "match": "P-value",
          "context": "at week 12 FOOTER: Two-sided P-values were estimated using a logis"
        },
        {
          "match": "P-value",
          "context": "and prior biologic exposure). P-values shown for sonelokimab 120\u2009mg"
        },
        {
          "match": "P-value",
          "context": "multiplicity-controlled. Raw P-values for sonelokimab 60\u2009mg NI are"
        }
      ]
    },
    "confidence_intervals": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "confidence interval",
        "95% ci"
      ],
      "examples": [
        {
          "match": "95% CI",
          "context": "ng. The ORs, risk difference, 95% CIs and estimated two-sided P va"
        },
        {
          "match": "95% CI",
          "context": "LSM difference between arms, 95% CIs and two-sided P values were"
        },
        {
          "match": "confidence interval",
          "context": "; BSA, body surface area; CI, confidence interval; ITT, intention-to-treat; NI,"
        }
      ]
    },
    "comparative_stats": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "odds ratio"
      ],
      "examples": [
        {
          "match": "odds ratio",
          "context": "-treat; NI, no induction; OR, odds ratio; PASI, Psoriasis Area and Sev"
        }
      ]
    },
    "non_parametric": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling": {
      "present": true,
      "count": 6,
      "unique_matches": [
        "mmrm"
      ],
      "examples": [
        {
          "match": "MMRM",
          "context": "ptively and analyzed using an MMRM including treatment arm, visi"
        },
        {
          "match": "MMRM",
          "context": "points were analyzed using an MMRM to account for missing data w"
        },
        {
          "match": "MMRM",
          "context": "values were estimated using a MMRM analysis including treatment"
        }
      ]
    },
    "assumption_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "survival_analysis": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "regression_and_models": {
      "present": true,
      "count": 4,
      "unique_matches": [
        "logistic regression"
      ],
      "examples": [
        {
          "match": "logistic regression",
          "context": "nd key secondary endpoints, a logistic regression model was used to test the pa"
        },
        {
          "match": "logistic regression",
          "context": "values were derived from the logistic regression model. To adjust for multiple"
        },
        {
          "match": "logistic regression",
          "context": "criptively and analyzed using logistic regression. An NRI method was used to ha"
        }
      ]
    },
    "reporting_guidelines": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "spirit"
      ],
      "examples": [
        {
          "match": "SPIRIT",
          "context": "thritis: 52-week results from SPIRIT-H2H studyPatient-reported out"
        },
        {
          "match": "SPIRIT",
          "context": "period of the phase III trial SPIRIT-P1Group for research and asse"
        }
      ]
    },
    "data_types": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "continuous"
      ],
      "examples": [
        {
          "match": "Continuous",
          "context": "or exploratory purposes only. Continuous endpoints were summarized des"
        },
        {
          "match": "Continuous",
          "context": "ed medication before week 12. Continuous endpoints were analyzed using"
        }
      ]
    },
    "dependency": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "repeated measures"
      ],
      "examples": [
        {
          "match": "repeated measures",
          "context": "s mean; MMRM, mixed model for repeated measures; NI, no induction; PBO, place"
        },
        {
          "match": "repeated measures",
          "context": "s mean; MMRM, mixed model for repeated measures; mNAPSI, modified Nail Psoria"
        }
      ]
    },
    "clustering": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "hierarchical"
      ],
      "examples": [
        {
          "match": "hierarchical",
          "context": "tested using a fixed-sequence hierarchical order. Once a null hypothesis"
        }
      ]
    },
    "missing_data": {
      "present": true,
      "count": 12,
      "unique_matches": [
        "missing data",
        "imputation"
      ],
      "examples": [
        {
          "match": "missing data",
          "context": "NRI method was used to handle missing data for the dichotomous primary a"
        },
        {
          "match": "missing data",
          "context": "using an MMRM to account for missing data when estimating treatment eff"
        },
        {
          "match": "missing data",
          "context": "9 (excluding one patient with missing data).bCalculated for n\u2009=\u200938 (excl"
        }
      ]
    },
    "effect_size": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "or",
        "odds ratio"
      ],
      "examples": [
        {
          "match": "odds ratio",
          "context": "-treat; NI, no induction; OR, odds ratio; PASI, Psoriasis Area and Sev"
        },
        {
          "match": "OR",
          "context": "n-to-treat; NI, no induction; OR, odds ratio; PASI, Psoriasis"
        }
      ]
    },
    "post_hoc": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "post hoc",
        "post-hoc"
      ],
      "examples": [
        {
          "match": "post-hoc",
          "context": "or axial spondyloarthritis: a post-hoc analysis of final safety data"
        },
        {
          "match": "post hoc",
          "context": "ase (mNAPSI\u2009=\u20090) was assessed post hoc. Safety endpoints were also a"
        }
      ]
    },
    "baseline_reporting": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "baseline characteristic"
      ],
      "examples": [
        {
          "match": "Baseline characteristic",
          "context": "ked to this article. CAPTION: Baseline characteristics FOOTER: BMI, body mass index"
        }
      ]
    },
    "advanced_modeling_extra": {
      "present": true,
      "count": 9,
      "unique_matches": [
        "excluded",
        "excluding"
      ],
      "examples": [
        {
          "match": "excluded",
          "context": "n the protocol. Patients were excluded if they had an active infecti"
        },
        {
          "match": "excluded",
          "context": "quivalent) at screening, were excluded, unless the following criteri"
        },
        {
          "match": "excluded",
          "context": "udy treatment initiation were excluded. Patients with concurrent mal"
        }
      ]
    },
    "systematic_review_metrics": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "diagnostic_metrics": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "sensitivity"
      ],
      "examples": [
        {
          "match": "sensitivity",
          "context": "must not have had known hypersensitivity to SLK or ADA, or any of thei"
        },
        {
          "match": "sensitivity",
          "context": "ivity, PtAAP, HAQ-DI and high-sensitivity C-reactive protein) and was m"
        },
        {
          "match": "sensitivity",
          "context": "body mass index; hs-CRP, high-sensitivity C-reactive protein.aCalculate"
        }
      ]
    },
    "model_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "domain_indicators": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "mouse model"
      ],
      "examples": [
        {
          "match": "mouse model",
          "context": "o inflamed joint tissues in a mouse model of collagen induced arthritis"
        }
      ]
    }
  }
}